CoChat

LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 – 2014)

Demeulemeester, Jonas, Chaltin, Patrick, Marchand, Arnaud, De Maeyer, Marc, Debyser, Zeger, Christ, Frauke · 2014 · Expert Opinion on Therapeutic Patents
Cited by 83

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Integration of the viral genome into the host cell chromatin is a central step in the replication cycle of the HIV. Blocking the viral integrase (IN) enzyme therefore provides an attractive therapeutic strategy, as evidenced by the recent clinical approval of three IN strand transfer inhibitors. Viral resistance and cross-resistance among these inhibitors, however, warrant the search for compounds targeting HIV integration through alternative mechanisms of action. AREAS COVERED: The most potent class of allosteric IN inhibitors was independently identified at the University of Leuven, Belgium, and at Boehringer Ingelheim, Canada. These compounds, coined LEDGINs (after the lens epithelium-derived growth factor/p75 cofactor binding pocket on IN) or non-catalytic site IN inhibitors (NCINIs) by the respective groups, have shown remarkable antiviral activity. This review provides a brief introduction to the compound class and discusses the recent patent literature (2006 to the present). EXPERT OPINION: LEDGINs are still early in development. Trials with clinical candidate BI-224436 were put on hold despite promising results. Literature, however, reveals that almost all major pharmaceutical companies active in the treatment of HIV/AIDS have taken a significant interest in this class. As a result, several of these inhibitors may soon enter clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/13543776.2014.898753

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 83

Metadata

Authors
Demeulemeester, J., Chaltin, P., Marchand, A., De Maeyer, M., Debyser, Z., & Christ, F.
Venue
Expert Opinion on Therapeutic Patents
Published
2014-03-25
Volume
24
Issue
6
Pages
609-632
ISSN
  • 1354-3776 (ISSN-L)
  • 1744-7674
OpenAlex
W1969081293
Cited by
83
References
22
FWCI
6.27
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 – 2014). https://app.cochat.ai/papers/10.1517/13543776.2014.898753
The paper
Demeulemeester, J., Chaltin, P., Marchand, A., De Maeyer, M., Debyser, Z., & Christ, F. (2014). LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 – 2014). Expert Opinion on Therapeutic Patents. https://doi.org/10.1517/13543776.2014.898753

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.